BUENOS AIRES, Argentina – In Colombia, guidelines for biosimilar regulation share a certain similarity with buses: wait for ages, then two come along at once. In August, three years after the Colombian government issued a decree mandating the ministry of health to establish regulations for biosimilars, two new guidelines – focusing on stability and immunogenicity – will be implemented.